COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
- 11 January 2024
- journal article
- research article
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (1) , e0328623
Abstract
Early COVID-19 convalescent plasma (CCP) transfusion to outpatients with COVID-19 decreases progression to hospitalization, but the mechanism of how CCP reduces severity is unknown. Among 882 COVID-19 participants transfused with CCP or control plasma in a randomized controlled trial, 21 cytokines and chemokines were measured using electrochemiluminescence assays. Wilcoxon rank sum tests were used to evaluate the difference between early (transfused within 5 days of symptom onset) CCP vs early control plasma and late (transfused 6–9 days after symptom onset) CCP vs late control plasma at each visit. Linear mixed-effect models were used to assess the difference in the slope of cytokine change. Median cytokine and chemokine levels were similar between the early CCP and early control groups pre-transfusion. At the day 14 visit, only the median IL-6 ( P = 0.014) and IL-16 ( P = 0.036) levels were lower in the early CCP group compared to the early control group, but these differences were not statistically significant after correcting for multiple comparisons (requiring P < 0.0024). IL-6 levels decreased significantly faster in the early CCP group from screening to the day 14 visit compared to the early control group ( P < 0.001). No difference was observed in the slope of cytokine change from screening to day 90 between early CCP and early control groups. Late control and late CCP arms showed similar cytokine and chemokine levels through study follow-up. One mechanism by which early CCP transfusion reduces hospitalization may be by decreasing IL-6 levels, as the reduction is associated with better recovery from COVID-19. IMPORTANCE: This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.Keywords
Funding Information
- U.S. Department of War (W911QY2090012)
- HHS | NIH | NIAID | National Institute of Allergy and Infectious Diseases (3R01AI152078-01S1)
- HHS | NIH | NIAID | National Institute of Allergy and Infectious Diseases (3R01AI120938-05S1)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK131926)
- HHS | NIH | National Heart, Lung, and Blood Institute (1K23HL151826)
- HHS | NIH | National Institute on Drug Abuse (F31DA054849)
- HHS | NIH | National Center for Advancing Translational Sciences (U24TR001609)
This publication has 29 references indexed in Scilit:
- Immunopathology of Hyperinflammation in COVID-19The American Journal of Pathology, 2021
- Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased MortalityThe American Journal of Pathology, 2020
- The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infectionJournal of Allergy and Clinical Immunology, 2020
- Pathogenesis of COVID-19 from the Perspective of the Damage-Response FrameworkmBio, 2020
- An inflammatory cytokine signature predicts COVID-19 severity and survivalNature Medicine, 2020
- Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in ChinaThe Journal of Infectious Diseases, 2020
- Deployment of convalescent plasma for the prevention and treatment of COVID-19Journal of Clinical Investigation, 2020
- Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditionsCytokine, 2020
- Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictorsEmerging Microbes & Infections, 2020
- Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancerNature Reviews Immunology, 2018